Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough. Their approach centers on this proprietary drug, targeting central and peripheral pathways. This specialized pharmacological strategy aims to provide symptomatic relief in this underserved therapeutic area.

Founded in 2011 in New Haven, CT, Trevi Therapeutics emerged from recognizing significant unmet needs in chronic symptom management. The company was established to advance Haduvio, leveraging its distinct mechanism of action as a potential treatment where existing therapies are insufficient. This insight initiated its drug development program.

Trevi Therapeutics focuses on patients suffering from chronic cough, aiming to improve quality of life. The company’s vision is to advance Haduvio through clinical development, making it a novel therapeutic option. They are committed to delivering meaningful advancements for individuals burdened by persistent cough.

High-Level Overview

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharmaceutical company dedicated to developing Haduvio™ (oral nalbuphine ER), its sole investigational therapy, to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and potentially non-IPF interstitial lung disease (ILD).[1][2][3][6] Haduvio targets the cough reflex arc centrally and peripherally as a kappa opioid agonist and mu antagonist (KAMA), addressing unmet needs in conditions with no approved U.S. therapies, serving patients whose quality of life is severely impacted by debilitating, untreatable cough.[1][3][6] The company demonstrated growth momentum in 2025 with positive Phase 2b CORAL trial results in IPF chronic cough and Phase 2a RIVER trial in RCC, showing statistically significant cough frequency reductions—the first such outcomes in these indications—while maintaining capital efficiency with Q3 2025 net loss of $11.8 million and R&D expenses of $10.1 million.[1][6]

Origin Story

Founded between 2011 and 2015, Trevi Therapeutics emerged from New Haven, Connecticut's burgeoning biotech ecosystem, leveraging local universities, industry collaborators like Alexion AstraZeneca and Pfizer, and a patient-centric focus on chronic cough hypersensitivity.[2][3][4][5] Under President and CEO Jennifer Good, the company honed its idea around Haduvio's novel mechanism targeting opioid receptors in the cough reflex arc, advancing it through clinical stages amid a fast-paced, entrepreneurial environment.[3][4][6] Early traction built through disciplined R&D, culminating in 2025's pivotal Phase 2 trial successes in IPF and RCC, positioning Trevi as a leader in specialty respiratory indications.[1][6]

Core Differentiators

• Unique Mechanism of Action: Haduvio is the first investigational therapy with statistically significant reductions in cough frequency for IPF chronic cough and RCC, acting as KAMA on central and peripheral opioid receptors without U.S. DEA scheduling for nalbuphine.[3][6]
• Focused Pipeline and Efficiency: Sole focus on Haduvio for high-need, untreatable chronic cough (affecting up to 10% of adults) enables capital discipline, with lower R&D spend year-over-year and positive late-stage data readouts.[1][2][6]
• Precision Targeting: Emphasizes specialty indications like IPF and RCC, using biomarkers for patient selection, extending potential to pruritus in liver diseases via oral small-molecule delivery superior to topicals or injectables.[2]
• Patient-Centric Culture: "All hands-on deck" in New Haven's biotech hub fosters innovation, collaboration, and community ties, driving rigorous development for quality-of-life improvements.[4][5]

Role in the Broader Tech Landscape

Trevi rides the wave of precision neurology and respiratory therapies, targeting cough hypersensitivity—a hypersensitive neural disorder in chronic conditions like IPF and RCC amid rising interstitial lung disease prevalence and post-pandemic cough awareness.[2][6] Timing aligns with no U.S.-approved treatments, creating first-mover advantage in a market burdened by patient, caregiver, and system costs, bolstered by positive 2025 trial data and New Haven's life-sciences growth.[1][3][5][6] Trevi influences the ecosystem by pioneering KAMA modulation, potentially expanding to pruritus and inspiring biomarker-driven biotech in underserved cardiorespiratory spaces.[2]

Quick Take & Future Outlook

Trevi's next catalysts include topline Phase 2b IPF data (already positive from 2025) and potential Phase 3 advancement for Haduvio, with earnings on March 17, 2026, amid a negative P/E of -38.41 signaling pre-revenue growth stage.[2][3] Trends like precision medicine, oral therapies for chronic conditions, and biotech efficiency will shape its path, evolving Trevi from clinical player to commercial leader in cough therapeutics. As the sole focused developer delivering breakthrough cough reductions, Trevi stands poised to transform untreatable suffering into manageable care.[1][6]